Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
267 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Show all (61)
  • (-) Currently Recruiting (8)
  • Closed (53)

Medical Condition

  • Show all (267)
  • Addiction (4)
  • Allergy, Asthma, & Immunology (1)
  • Autoimmune Disorders (3)
  • Bone & Muscle (2)
  • Cancer (38)
    • (-) Bladder Cancer (4)
    • Brain Cancer (1)
    • Breast Cancer (7)
    • Gynecologic Cancer (3)
    • Leukemia (3)
    • Liver Cancer (2)
    • Lung Cancer (2)
    • Lymphoma (1)
    • Pancreatic Cancer (1)
    • Prostate Cancer (2)
  • COVID-19 (Coronavirus) (8)
  • Diabetes (6)
  • Ear, Nose and Throat (6)
  • Endocrine & Metabolic Disease (2)
  • Gastrointestinal and Digestive Diseases (5)
  • Hair and Skin Disorders (2)
  • Healthy Volunteers (46)
  • Heart Disease (20)
  • Infectious Disease (11)
  • Liver Disease (13)
  • Lung Disease (2)
  • Neurological Disorders (35)
    • Alzheimer's Disease (7)
    • (-) Brain Tumors (4)
    • Cerebral Palsy (2)
    • Dementia (3)
    • Huntington's Disease (1)
    • Multiple Sclerosis (3)
    • Neuromuscular (2)
    • Neuropathy (1)
    • Parkinson's Disease (2)
  • Nutrition (1)
  • Obesity (9)
  • Obstetrics & Gynecology (11)
  • Pediatrics (19)
  • Psychiatric Disorders (7)
  • Rehabilitation (1)
  • Stroke (2)
  • Transplant (12)
  • Vascular Conditions (1)
Displaying 1 - 8 of 8

FORAGER-1: A Phase 1 Clinical Trial of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors with FGFR3 mutations

Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
You are being asked to participate in this study because you have cancer that is late in stage or spread to other parts of the body that includes the lining of urinary tract. The purpose of this study is to see whether LY3866288 is safe, the possible side effects, how well your disease responds to treatment study drug and which does level of study drug…
Read More

A phase 2 trial for muscle-invasive bladder cancer using enfortumab vedotin plus pembrolizumab without the need for cystectomy or surgery.

Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to see if the combination of enfortumab vedotin and pembrolizumab leads to no detectable cancer on early assessments of the bladder after initial treatment. We are asking you to take part in this research study because you have muscle-invasive bladder cancer. This combination of enfortumab vedotin and pembrolizumab has been…
Read More

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (LOXO-LNC-24001)

Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to determine whether using LY4052031 in a type of cancer that may have tumor cells that express a protein called Nectin-4 is safe and how well the cancer responds to the study drug. LY4052031 has not been approved by the US Food and Drug Administration (FDA). This is a first in human study and all of the risks are not fully…
Read More

HDWI High Grade Glioma Brain MRI

Condition: Neurological Disorders / Brain Tumors
Investigator: Tony J. Wang, MD
Status: Currently Recruiting
The purpose of this study is to find out if performing Magnetic Resonance Image (MRI) scans of your brain with adaptive planning during your radiation treatment of your high-grade glioma will help determine how sensitive the images collected of the brain are at detecting the response of the tumor to the cancer treatment. In this study, four or seven MRI…
Read More

NeoSTOP-IT: Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer

Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is for patients with a localized bladder cancer called muscle-invasive bladder cancer. Muscle-invasive bladder cancer is usually treated with a combination of chemotherapy and surgery. This surgery removes the entire bladder, which changes how they urinate for the rest of their life. Some patients will have a small opening in the…
Read More

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Patients with Relapsed or Refractory PCNSL

Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
This study is being done to test the orally administered study drug, CA-4948 alone, in combination with ibrutinib, or ibrutinib alone in adult patients ages 18 and over diagnosed with relapsed or refractory (RR) Primary Central Nervous System Lymphoma (PCNSL). This study will take place at multiple centers globally. The study drug, CA-4948, is thought to…
Read More

EF-41/KEYNOTE-D58: Study of Optune Concomitant with Temozolomide plus Pembrolizumab in Newly Diagnosed Glioblastoma

Condition: Neurological Disorders / Brain Tumors
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
The purpose of this study is to compare the effects of pembrolizumab simultaneously with the Optune device and maintenance temozolomide(TMZ) versus placebo simultaneously with Optune and maintenance TMZ for the study treatment of newly diagnosed GBM. In this study, a placebo is an inactive substance that looks the same as and is given the same way as…
Read More

Study of Focused Ultrasound (FUS) with DEFINITY Microbubbles in Children and Young Adults with Progressive Diffuse Midline Glioma (DMG)

Condition: Neurological Disorders / Brain Tumors
Investigator: Stergios Zacharoulis, MD
Status: Currently Recruiting
Children and young adults with diffuse midline glioma will be treated with Focused Ultrasound (FUS) with DEFINITY microbubbles and neuro-navigator-controlled sonication. The overall goal of this study is to see if the study treatment plan will improve the outcome of participants with diffuse midline glioma, for which no known cure exists, and determine…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2026 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science